Key result
ACS during COVID-19 infection is linked to ~2.5-fold higher rates of depressive symptoms.
Why the study?
SARS-CoV-2 infection is associated with cardiovascular and mental health complications, but the prevalence of somatic and cognitive depressive symptoms in patients with concomitant cardiovascular disease required evaluation.
Does concomitant acute coronary syndrome increase the prevalence of depressive symptoms in patients recovering from SARS-CoV-2 infection?
Cross-Sectional (n=101)
Yes
Does concomitant acute coronary syndrome increase the prevalence of depressive symptoms in patients recovering from SARS-CoV-2 infection?
Absolute Event Rate: 98% vs 40%
p-value: p=<0.001
Patients recovering from SARS-CoV-2 infection with concomitant acute coronary syndrome exhibit a significantly higher burden of cognitive and somatic depressive symptoms compared to those without ACS.
In 2020, the World Health Organization (WHO) declared the outbreak of Coronavirus disease 19 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Besides well-known pulmonary complications, other frequent detrimental health consequences included cardiovascular, thromboembolic, and mental health disorders. A high incidence of acute coronary syndromes (ACSs) with both short- and long-term outcomes was influenced by the disease severity and related complications, including mental health challenges, depression, and anxiety. The aim of our study was to analyze the prevalence of depressive symptoms (somatic and cognitive) in patients with SARS-CoV-2 infection and concomitant cardiovascular disease (CVD). Depression screening was conducted in 101 patients who survived SARS-CoV-2 infection during the 2020-2022 period. Of the study sample, 54 (53.5%) were female, and 47 (46.5%) were male, with the mean age of 55 (15.9 SD) years. All participants completed the Beck Depression Inventory (BDI) one to three months after hospital discharge. Patients with SARS-CoV-2 and ACS demonstrated a higher frequency of depressive symptoms compared to COVID-19-only patients without ACS. Statistically significant differences were observed in somatic symptoms (sleeplessness, irritability, loss of appetite, difficulties in concentration, tiredness), as well as in cognitive symptoms (loneliness, sadness, crying, fatigue, self-hatred, loss of interests, devaluation, indecision, and agitation). Our study findings suggest that acute severe illness (SARS-CoV-2 and ACS), elderly age, and the presence of chronic diseases can contribute to depressive mood. These observations highlight the need for multidisciplinary care involving cardiologists, neurologists, psychiatrists, and rehabilitation specialists with a comprehensive assessment of depressive symptoms and consideration of classical risk factors, which can potentially affect prognosis. However, these findings should be interpreted as associative, given the cross-sectional design of the study and the presence of confounding factors.
No takes yet. Share an insight, caveat, or question.
Gonjilashvili et al. (2026) conducted a cross-sectional in SARS-CoV-2 and Acute Coronary Syndrome (n=101). Acute Coronary Syndrome (ACS) vs. SARS-CoV-2 without ACS was evaluated on Depressive symptoms score >10 on the Beck Depression Inventory (p=<0.001). Concomitant acute coronary syndrome in SARS-CoV-2 survivors was associated with a significantly higher prevalence of depressive symptoms compared to SARS-CoV-2 alone (98% vs 40%, p<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: